432 related articles for article (PubMed ID: 27029056)
1. Treatment of newly diagnosed B-cell origin primary CNS lymphoma with systemic R-IDARAM chemotherapy and intrathecal immunochemotherapy.
Qian L; Zhou C; Shen J; Cen J; Yin W
Oncotarget; 2016 May; 7(18):25783-90. PubMed ID: 27029056
[TBL] [Abstract][Full Text] [Related]
2. [Therapeutic management of central nervous system lymphomas in a single hematological institute].
Iványi JL; Marton E; Plander M; Gyánó G; Czumbil L; Tóth C
Orv Hetil; 2009 Oct; 150(42):1937-44. PubMed ID: 19812012
[TBL] [Abstract][Full Text] [Related]
3. Combined treatment of rituximab, idarubicin, dexamethasone, cytarabine, methotrexate with radiotherapy for primary central nervous system lymphoma.
Zhao D; Qian L; Shen J; Liu X; Mei K; Cen J; Wang Y; Li C; Ma Y
J Cell Mol Med; 2014 Jun; 18(6):1081-6. PubMed ID: 24628986
[TBL] [Abstract][Full Text] [Related]
4. The development of targeted chemotherapy for CNS lymphoma-a pilot study of the IDARAM regimen.
Moreton P; Morgan GJ; Gilson D; Smith GM; McVerry BA; Davies JM; Mackie MJ; Bolam S; Jalihal SS; Howard MR; Parapia LA; Williams AT; Child JA;
Cancer Chemother Pharmacol; 2004 Apr; 53(4):324-8. PubMed ID: 14704830
[TBL] [Abstract][Full Text] [Related]
5. Primary central nervous system lymphoma: results of a pilot and phase II study of systemic and intraventricular chemotherapy with deferred radiotherapy.
Pels H; Schmidt-Wolf IG; Glasmacher A; Schulz H; Engert A; Diehl V; Zellner A; Schackert G; Reichmann H; Kroschinsky F; Vogt-Schaden M; Egerer G; Bode U; Schaller C; Deckert M; Fimmers R; Helmstaedter C; Atasoy A; Klockgether T; Schlegel U
J Clin Oncol; 2003 Dec; 21(24):4489-95. PubMed ID: 14597744
[TBL] [Abstract][Full Text] [Related]
6. Treatment of diffuse large B-cell lymphoma with secondary central nervous system involvement: encouraging efficacy using CNS-penetrating R-IDARAM chemotherapy.
Maciocia P; Badat M; Cheesman S; D'Sa S; Joshi R; Lambert J; Mohamedbhai S; Pule M; Linch D; Ardeshna K
Br J Haematol; 2016 Feb; 172(4):545-53. PubMed ID: 26684148
[TBL] [Abstract][Full Text] [Related]
7. Methotrexate-cytarabine-dexamethasone combination chemotherapy with or without rituximab in patients with primary central nervous system lymphoma.
Sun X; Liu J; Wang Y; Bai X; Chen Y; Qian J; Zhu H; Liu F; Qiu X; Sun S; Ji N; Liu Y
Oncotarget; 2017 Jul; 8(30):49156-49164. PubMed ID: 28467782
[TBL] [Abstract][Full Text] [Related]
8. Treatment of secondary central nervous system lymphoma with intrathecal rituximab, high-dose methotrexate, and R-DHAP followed by autologous stem cell transplantation: results of the HOVON 80 phase 2 study.
Doorduijn JK; van Imhoff GW; van der Holt B; Schouten HC; Schaafsma MR; MacKenzie MA; Baars JW; Kersten MJ; Lugtenburg PJ; van den Bent MJ; Enting RH; Spoelstra FM; Poortmans P; Bromberg JEC
Hematol Oncol; 2017 Dec; 35(4):497-503. PubMed ID: 27530779
[TBL] [Abstract][Full Text] [Related]
9. High-dose chemotherapy and autologous stem cell transplant compared with conventional chemotherapy for consolidation in newly diagnosed primary CNS lymphoma--a randomized phase III trial (MATRix).
Schorb E; Finke J; Ferreri AJ; Ihorst G; Mikesch K; Kasenda B; Fritsch K; Fricker H; Burger E; Grishina O; Valk E; Zucca E; Illerhaus G
BMC Cancer; 2016 Apr; 16():282. PubMed ID: 27098429
[TBL] [Abstract][Full Text] [Related]
10. Role of chemotherapy additional to high-dose methotrexate for primary central nervous system lymphoma (PCNSL).
Bergner N; Monsef I; Illerhaus G; Engert A; Skoetz N
Cochrane Database Syst Rev; 2012 Nov; 11():CD009355. PubMed ID: 23152274
[TBL] [Abstract][Full Text] [Related]
11. High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial.
Thiel E; Korfel A; Martus P; Kanz L; Griesinger F; Rauch M; Röth A; Hertenstein B; von Toll T; Hundsberger T; Mergenthaler HG; Leithäuser M; Birnbaum T; Fischer L; Jahnke K; Herrlinger U; Plasswilm L; Nägele T; Pietsch T; Bamberg M; Weller M
Lancet Oncol; 2010 Nov; 11(11):1036-47. PubMed ID: 20970380
[TBL] [Abstract][Full Text] [Related]
12. Combined systemic and intraventricular chemotherapy in primary CNS lymphoma: a pilot study.
Schlegel U; Pels H; Glasmacher A; Kleinschmidt R; Schmidt-Wolf I; Helmstaedter C; Fliessbach K; Deckert M; Van Roost D; Fimmers R; Bode U; Klockgether T
J Neurol Neurosurg Psychiatry; 2001 Jul; 71(1):118-22. PubMed ID: 11413277
[TBL] [Abstract][Full Text] [Related]
13. Phase II trial of chemotherapy alone for primary CNS and intraocular lymphoma.
Sandor V; Stark-Vancs V; Pearson D; Nussenblat R; Whitcup SM; Brouwers P; Patronas N; Heiss J; Jaffe E; deSmet M; Kohler D; Simon R; Wittes R
J Clin Oncol; 1998 Sep; 16(9):3000-6. PubMed ID: 9738568
[TBL] [Abstract][Full Text] [Related]
14. Primary non-Hodgkin's lymphoma of the CNS treated with CHOD/BVAM or BVAM chemotherapy before radiotherapy: long-term survival and prognostic factors.
Bessell EM; Graus F; Lopez-Guillermo A; Lewis SA; Villa S; Verger E; Petit J
Int J Radiat Oncol Biol Phys; 2004 Jun; 59(2):501-8. PubMed ID: 15145169
[TBL] [Abstract][Full Text] [Related]
15. Immunochemotherapy with intensive consolidation for primary CNS lymphoma: a pilot study and prognostic assessment by diffusion-weighted MRI.
Wieduwilt MJ; Valles F; Issa S; Behler CM; Hwang J; McDermott M; Treseler P; O'Brien J; Shuman MA; Cha S; Damon LE; Rubenstein JL
Clin Cancer Res; 2012 Feb; 18(4):1146-55. PubMed ID: 22228634
[TBL] [Abstract][Full Text] [Related]
16. A phase 1 dose escalation study of idarubicin combined with methotrexate, vindesine, and prednisolone for untreated elderly patients with primary central nervous system lymphoma. The GOELAMS LCP 99 trial.
Olivier G; Clavert A; Lacotte-Thierry L; Gardembas M; Escoffre-Barbe M; Brion A; Cumin I; Legouffe E; Solal-Celigny P; Chabin M; Ingrand P; Colombat P; Delwail V
Am J Hematol; 2014 Nov; 89(11):1024-9. PubMed ID: 25052698
[TBL] [Abstract][Full Text] [Related]
17. Immunochemotherapy with rituximab, methotrexate, procarbazine, and lomustine for primary CNS lymphoma (PCNSL) in the elderly.
Fritsch K; Kasenda B; Hader C; Nikkhah G; Prinz M; Haug V; Haug S; Ihorst G; Finke J; Illerhaus G
Ann Oncol; 2011 Sep; 22(9):2080-2085. PubMed ID: 21303800
[TBL] [Abstract][Full Text] [Related]
18. Modified IDARAM chemotherapy regimen for primary central nervous system lymphoma: experience of three cases.
Yilmaz M; Erkutlu I; Kilciksiz S; Pehlivan M; Okan V; Alptekin M; Sari I
Hematology; 2008 Apr; 13(2):107-13. PubMed ID: 18616878
[TBL] [Abstract][Full Text] [Related]
19. Central nervous system relapse of systemic non-Hodgkin's lymphoma: results of treatment based on high-dose methotrexate combination chemotherapy.
Bokstein F; Lossos A; Lossos IS; Siegal T
Leuk Lymphoma; 2002 Mar; 43(3):587-93. PubMed ID: 12002763
[TBL] [Abstract][Full Text] [Related]
20. Outcomes of older patients with primary central nervous system lymphoma treated in routine clinical practice in the UK: methotrexate dose intensity correlates with response and survival.
Martinez-Calle N; Poynton E; Alchawaf A; Kassam S; Horan M; Rafferty M; Kelsey P; Scott G; Culligan DJ; Buckley H; Lim YJ; Ngu L; McCulloch R; Rowntree C; Wright J; McKay P; Fourali S; Eyre TA; Smith J; Osborne W; Yallop D; Linton K; Fox CP; Cwynarski K
Br J Haematol; 2020 Aug; 190(3):394-404. PubMed ID: 32232989
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
